Portada›Viernes 19 de septiembre de 2025

Biomédicas del NASDAQ ante la SEC, viernes 19 de septiembre de 2025

Los 31 documentos que 27 empresas del sector presentaron ante la SEC ese día, agrupados por tipo y con el enlace al original en EDGAR.

← jueves 18 de septiembre de 2025 · lunes 22 de septiembre de 2025 →

¿Lo quieres en tu correo cada mañana, y solo de tus empresas? Crear una cuenta.

Emisiones y dilución

1. BCDABioCardia, Inc.424B4Nueva emisión de acciones con precioEDGAR
2. CNSPCNS Pharmaceuticals, Inc.424B5Nueva emisión de acciones con precioEDGAR
   En el documentoContrasplit de accionestexto original ▸

   …stock. Delisting also could have other negative results, including the potential loss of employee confidence, the loss of institutional investors or interest in business development opportunities. We completed a reverse stock split on July 22, 2025 and we cannot predict the effect that such reverse stock split will have on the market price for shares of our common stock. We completed a 1-for-12 reverse stock split of our common…
3. COCPCocrystal Pharma, Inc.S-1Capacidad de emisión registradaEDGAR
   En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

   …to continue as a going concern. In addition, our independent registered public accounting firm, in its audit report to the financial statements as of and for the year ended December 31, 2024, expressed substantial doubt about our ability to continue as a going concern. Our continued existence is dependent upon our obtaining the necessary capital to meet our expenditures, and we can provide no assurance that we will be able to raise adequate capital to meet our future…

   En el documentoAviso de incumplimiento de las reglas de cotizacióntexto original ▸

   …minimum bid requirement, we effected a 1-for-12 reverse stock split by amending our Certificate of Incorporation on October 11, 2022. Further, previously in December 2019 and again in November 2020, we received notice of failure to comply with the Nasdaq minimum bid price although were able to regain compliance without effecting a reverse stock split in those instances. In addition, a new Nasdaq rule recently took effect which precludes listed issuers that have already…

   En el documentoContrasplit de accionestexto original ▸

   …price requirement because the closing bid price of our common stock was below $1.00 per share for 30 consecutive trading days. In order to regain compliance with the Nasdaq minimum bid requirement, we effected a 1-for-12 reverse stock split by amending our Certificate of Incorporation on October 11, 2022. Further, previously in December 2019 and again in November 2020, we received notice of failure to comply with the Nasdaq minimum bid price…
4. EQEquillium, Inc.424B5Nueva emisión de acciones con precioEDGAR
5. GOVXGeoVax Labs, Inc.424B5Nueva emisión de acciones con precioEDGAR
6. JSPRJasper Therapeutics, Inc.424B5Nueva emisión de acciones con precioEDGAR
   En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

   …June 30, 2025, we had an accumulated deficit of $288.8 million. Given our recurring losses from operations and negative cash flows, and based on our current operating plan, we concluded that there is substantial doubt about our ability to continue as a going concern within one year from August 13, 2025, the date we filed our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025. Implications of Being a Smaller Reporting Company We are a “smaller reporting…
7. LGVNLongeveron Inc.424B5Nueva emisión de acciones con precioEDGAR
   En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

   …in this prospectus as well as other information we include in this prospectus. Going Concern Opinion Our working capital deficiency, stockholders’ deficit, and recurring losses from operations raise substantial doubt about our ability to continue as a going concern. As a result, our independent registered public accounting firm included an explanatory paragraph in its report on our financial statements for the year ended December 31, 2024 with respect to this uncertainty…

   En el documentoPrograma de venta continua de acciones (ATM)texto original ▸

   …htm PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-286217 PROSPECTUS SUPPLEMENT (To Prospectus dated April 4, 2025) Up to $10,700,000 Class A Common Stock We have entered into an At The Market Offering Agreement, or the sales agreement, with H.C. Wainwright & Co., LLC, or Wainwright, dated September 19, 2025, relating to the sale of shares of our Class A Common Stock, par value $0.001 per share, or…
8. MPLTMapLight Therapeutics, Inc.S-1Capacidad de emisión registradaEDGAR
   En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

   …acceptable terms, could cause us to delay, limit, reduce or terminate our product development or future commercialization efforts. • Our recurring losses from operations and financial condition raise substantial doubt about our ability to continue as a going concern. • If we are unable to successfully identify, develop and commercialize any product candidates or experience significant delays in doing so, our business, financial condition, results of operations and…
9. PPBTPURPLE BIOTECH LTD.424B5Nueva emisión de acciones con precioEDGAR
   En el documentoPrograma de venta continua de acciones (ATM)texto original ▸

   …Registration No. 333-268710 PROSPECTUS SUPPLEMENT (To Prospectus dated May 22, 2023) Up to $2,300,000 American Depositary Shares each representing two hundred (200) Ordinary Shares Purple Biotech Ltd. We have entered into an At The Market Offering Agreement, dated September 19, 2025 (the “Sales Agreement”), with H.C. Wainwright & Co., LLC (“Wainwright”) relating to the offer and sale from time to time of American Depositary Shares (“ADSs”) offered…
10. SCNXScienture Holdings, Inc.424B5Nueva emisión de acciones con precioEDGAR
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸

    …1 form424b5.htm 424B5 Filed pursuant to Rule 424(b)(5) Registration No. 333-289198 Prospectus Supplement (To Prospectus dated August 8, 2025) Up to $9,200,000 Common Stock Scienture Holdings, Inc. has entered into an Equity Distribution Agreement (the “ATM Sales Agreement”) with Maxim Group LLC (“Maxim”) relating to the sale of shares of our common stock, par value $0.00001 per share, offered by this prospectus supplement. In accordance with the terms of the ATM Sales…
11. SNGXSOLIGENIX, INC.S-1Capacidad de emisión registradaEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

    …have incurred significant losses since inception and expect to continue to incur losses for the foreseeable future, which together with our negative cash flows and auditor’s going concern opinion raise substantial doubt about our ability to continue as a going concern without obtaining additional capital. ● We expect a number of factors to cause our operating results to fluctuate on a quarterly and annual basis, which may make it difficult to predict our future performance…

    En el documentoContrasplit de accionestexto original ▸

    …However, there can be no assurances that it can consummate such a transaction, or consummate a transaction at favorable pricing. F-27 Table of Contents Reverse Stock Split ​ On June 5, 2024, the Company completed a reverse stock split of its issued and outstanding shares of common stock at a ratio of one-for-sixteen, whereby every sixteen shares of the Company’s issued and outstanding common stock were automatically combined into one…
12. MBRXMoleculin Biotech, Inc.S-3Capacidad de emisión registradaEDGAR

Participaciones y control

1. BFRIBiofrontera Inc.SC 13D/ACambio en participación significativaEDGAR
   En el documentoContrasplit de accionestexto original ▸

   …involving the issuance of Issuer equity securities and/or rights, resulting in substantial dilution to BFAG. In addition, according to such filings, effective as of 11:59 pm on July 3, 2023, the Issuer effected a 1-for-20 reverse stock split of its then outstanding shares of common stock (the "Reverse Stock Split"). As a result of the Reverse Stock Split, the 8,000,000 shares of Issuer common stock held by BFAG immediately following the IPO…
2. VORVor Biopharma Inc.SC 13D/ACambio en participación significativaEDGAR
   En el documentoContrasplit de accionestexto original ▸

   …Current Report on Form 8-K, filed with the SEC on September 17, 2025. The share numbers in this Amendment No. 6 give effect to a 1-for-20 reverse split of the outstanding shares of the Issuer's common stock effected on September 18, 2025 (the "Reverse Stock Split"). Item 2. Identity and Background (a) This Schedule 13D/A is being filed on behalf of RA Capital Management, L.P. ("RA Capital"), Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P.…
3. ARTLARTELO BIOSCIENCES, INC.SC 13DCambio en participación significativaEDGAR
4. HYPDHYPERION DEFI, INC.SC 13D/ACambio en participación significativaEDGAR
5. LBRXLB PHARMACEUTICALS INCSC 13DCambio en participación significativaEDGAR
6. ORKAOruka Therapeutics, Inc.SC 13D/ACambio en participación significativaEDGAR
7. PGENPRECIGEN, INC.SC 13D/ACambio en participación significativaEDGAR

Informes y hechos relevantes

1. CTORCITIUS ONCOLOGY, INC.8-KVenta de acciones no registrada (colocación privada)EDGAR
2. PRLDPrelude Therapeutics Inc8-KOtros hechos relevantesEDGAR
   En el documentoAviso de incumplimiento de las reglas de cotizacióntexto original ▸

   …Bid Price Requirement because its common stock, par value $0.0001 per share (the "Common Stock") had failed to meet the $1.00 per share Minimum Bid Price Requirement. On September 18, 2025, the Company received a letter from Nasdaq notifying the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) and that the matter is now closed. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of…
3. BCDABioCardia, Inc.8-KOtros hechos relevantesEDGAR
4. EQEquillium, Inc.8-KOtros hechos relevantesEDGAR
5. IMDXInsight Molecular Diagnostics Inc.8-KCambio en el consejo o la direcciónEDGAR
6. JANXJanux Therapeutics, Inc.8-KCambio en el consejo o la direcciónEDGAR
7. JSPRJasper Therapeutics, Inc.8-KNuevo acuerdo materialEDGAR
8. LGVNLongeveron Inc.8-KNuevo acuerdo materialEDGAR
   En el documentoPrograma de venta continua de acciones (ATM)texto original ▸

   …standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 1.01. Entry into a Material Definitive Agreement. On September 19, 2025, Longeveron Inc., a Delaware corporation (the “Company”), entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”) providing for the sale and issuance by the Company of shares of its Class A common stock, par value $0.001 per share (the…

Juntas de accionistas

1. HRTXHERON THERAPEUTICS, INC. /DE/DEF 14AConvocatoria de junta de accionistasEDGAR
2. LFVNLifevantage CorpDEF 14AConvocatoria de junta de accionistasEDGAR
3. PAHCPHIBRO ANIMAL HEALTH CORPDEF 14AConvocatoria de junta de accionistasEDGAR
4. TECHBIO-TECHNE CorpDEF 14AConvocatoria de junta de accionistasEDGAR

← jueves 18 de septiembre de 2025 · lunes 22 de septiembre de 2025 →

Esto mismo, cada mañana y solo de tus empresas. Sigue a las que te interesen y recibe en tu correo lo que presenten ante la SEC, en castellano. Crear una cuenta. ¿Ya tienes cuenta? Entrar.

Esto no son recomendaciones de inversión. Son hechos públicos verificables en su fuente. Lee siempre el documento original antes de decidir nada. Aviso legal.